State of New Jersey Common Pension Fund D Makes New $660,000 Investment in Disc Medicine, Inc. $IRON

State of New Jersey Common Pension Fund D acquired a new stake in Disc Medicine, Inc. (NASDAQ:IRON) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 8,306 shares of the company’s stock, valued at approximately $660,000.

Other hedge funds have also bought and sold shares of the company. Aster Capital Management DIFC Ltd acquired a new stake in Disc Medicine during the 3rd quarter worth about $38,000. KBC Group NV acquired a new position in shares of Disc Medicine in the 4th quarter valued at about $80,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Disc Medicine by 36.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock valued at $146,000 after purchasing an additional 490 shares in the last quarter. Avanza Fonder AB boosted its position in shares of Disc Medicine by 14.1% during the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock valued at $151,000 after purchasing an additional 235 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in Disc Medicine by 15,137.5% during the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock worth $161,000 after purchasing an additional 2,422 shares during the period. Institutional investors own 83.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on IRON shares. Cantor Fitzgerald lowered their target price on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. UBS Group restated an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Raymond James Financial reaffirmed a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. Morgan Stanley set a $75.00 price objective on shares of Disc Medicine in a research note on Tuesday, February 17th. Finally, Wells Fargo & Company boosted their target price on shares of Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $104.80.

Insider Buying and Selling at Disc Medicine

In other news, CEO John D. Quisel sold 13,264 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $833,775.04. Following the completion of the sale, the chief executive officer directly owned 226,064 shares of the company’s stock, valued at $14,210,383.04. The trade was a 5.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jonathan Yen-Wen Yu sold 3,231 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $203,100.66. Following the completion of the sale, the chief operating officer owned 54,324 shares in the company, valued at $3,414,806.64. This represents a 5.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 59,410 shares of company stock worth $3,840,013 in the last ninety days. 3.76% of the stock is currently owned by corporate insiders.

Disc Medicine Stock Performance

Shares of Disc Medicine stock opened at $69.23 on Tuesday. The business has a 50-day simple moving average of $65.09 and a 200 day simple moving average of $75.68. Disc Medicine, Inc. has a one year low of $40.00 and a one year high of $99.50. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. The firm has a market capitalization of $2.64 billion, a price-to-earnings ratio of -10.46 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). On average, research analysts anticipate that Disc Medicine, Inc. will post -6.77 earnings per share for the current fiscal year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.